Launches Centre of Genomics

Metropolis Healthcare Limited, India’s second-largest pathology laboratory chain, today announced the launch of its Centre of Genomics, marking a significant step in scaling its longstanding capabilities in advanced genomics, precision medicine, molecular diagnostics, and genomic research.

The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties.

Commenting on the launch, Ms. Ameera Shah, Promoter and Executive Chairperson of the company, said:

• Genomics marks a decisive inflection point for diagnostics in India, expanding the role of laboratories from disease detection to risk prediction, therapy personalisation, and long-term disease management.
• As genomics increasingly informs lifelong medical decisions, leadership in this space is defined not by adoption alone, but by rigorous validation, deep expertise, quality assurance, and clinical responsibility. Through the Centre of Genomics, we bring together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations.
• Supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms.

Refer to Metropolis Healthcare News for detailed information.

Currently the stock is trading at INR 1890 (up 0.85%) on the National Stock Exchange.

Also Read – Amagi Media Labs IPO Review

1 APRIL 2019

Metropolis Healthcare Limited – one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan) is planning to raise INR 1,200.2 Cr to INR 1,204.29 Cr (all OFS) via initial public offer (IPO)

Metropolis Healthcare – Company Profile

Established in the year 1980, Mumbai based Metropolis Healthcare is a chain of diagnostics companies.

The Company mainly focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports.

The Company conducts its operations through its laboratory and service network. As of March 31, 2018, Metropolis laboratory network consists of 106 clinical laboratories and its service network comprises 1,130 patient touch points (out of which 28 are located outside India)

It also offers customized wellness packages to our institutional customers as per their requirement.

Metropolis Healthcare Limited – Business Activities

Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles, which are used for diagnostic screening, early detection, prediction, confirmation and/or monitoring of the disease.

Its tests are broadly classified into 3 categories –

Routine tests: such as blood chemistry analyses, blood cell counts and urine examination;

Semi-specialized tests: such as thyroid function tests, viral and bacterial cultures, histology, cytology, and infectious disease tests; and

Specialized tests: such as tests for coagulation studies, autoimmunity tests, cytogenetics, and molecular diagnostics.

As of March 31, 2018, the company offered a broad range of approximately 3,480 clinical laboratory tests and 524 profiles.

Metropolis also offers analytical and support services to clinical research organizations for their clinical research projects.

Metropolis Healthcare – Network

The Company have implemented a hub and spoke model for quick and efficient delivery of services through its widespread laboratory and service network, which covers 173 cities in India, as of March 31, 2018.

Outside India, the company has laboratory operations in Ghana, Kenya, Zambia, Mauritius, and Sri Lanka. In addition, Metropolis has also entered into agreements with 3rd parties for collection and processing of specimens in Nepal, Nigeria, UAE, and Oman.

As of March 31, 2018, the company has an operational network of 17 clinical laboratories, 28 patient touch points, and 7 ARCs, outside India.

Management Team

Metropolis has 4,585 full-time employees, including 183 pathologists and doctors and 2,022 scientific officers and phlebotomists located in India, and 222 full-time employees located outside India.

Promoters of Metropolis Healthcare

Dr. Sushil Kanubhai Shah,

Ameera Sushil Shah and

Metz Advisory LLP

IPO Opening / Closing Date

IPO Details – Price, Minimum Bid and Other

Metropolis Healthcare – Financials

Top-line

Metropolis posted steady revenue growth in the last three years. Revenue for FY 2016 stood at INR 490.60 Cr and the same was stood at INR 651.60 Cr for the period ended 31 March 2018

Bottom-line

Same as top-line, the company able to post steady growth in the bottom-line. Metropolis reported a Net Profit of INR 81.95 Cr for FY 2016 and the same was stood at INR 109.75 Cr for the period ended 31 March 2018

CONCLUSION –

Considering the company’s valuation and financial parameters, FinBlab recommends SUBSCRIBE ratings on Metropolis Healthcare Limited IPO

If you enjoyed this article, maybe your friends will too. Why not share it?

Also read, Finblab recommendation on Rail Vikas Nigam Limited IPO

5 Lessons To Learn From Long Term Investors

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I ( Vishal Dalwadi ) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Metropolis Healthcare Limited IPO: Review, Update appeared first on Upcoming ipos: Latest news on stocks, economy & finance.

Q2 FY 2019-20 Numbers

Metropolis Healthcare Limited, a complete chain of diagnostic companies with its central laboratory in Mumbai, Maharashtra has posted its Q2 FY 2019-20 numbers today. Read standalone details –

Revenue from operations stood at INR 172.28 crore in September 2019 up 16.61 percent Y-O-Y basis from INR 147.74 crore in September 2018. Q-O-Q revenues grew by 9.77 percent (INR 156.95 crore for June 2019)

Quarterly Net Profit at INR 31.68 crore in September 2019 up 72.87 percent Q-O-Q basis from INR 18.32 crore in June 2019. Y-O-Y profit up by 58.03 percent (INR 20.04 crore for September 2018)

Metropolis EPS has increased to Rs. 6.31 in September 2019 from Rs. 3.65 in June 2019.

Read: MEGHMANI ORGANICS Q2 Numbers

Total patient visit has increased from 4.23 Mn in H1FY19 to 4.92 Mn in H1FY20 registering a growth of 16.3 percent Y-O-Y

Number of tests performed has increased to 9.51 Mn in H1FY20 from 7.91 Mn in H1FY19 registering a growth of 20.3 percent Y-O-Y (consolidated)

Managing Director Said –

I am happy to present our quarterly and half yearly results.

We have been witnessing a consistent and stable growth in number of tests and patient visits. This is evident from the increase in revenue contribution from our retail business which reinforces patient trust and preference for Metropolis.

In our endeavor to offer tests that are critical for correct diagnosis, we have added 14 new specialized tests in the area of oncology, genetics and transplant pathology.

We are also pleased to welcome aboard Ms. Ishita Medhekar in the role of CHRO and Mr Rakesh Agarwal as CFO.

We will continue to be driven in our pursuit to deliver excellence in pathology while delivering value for all our stakeholders.

Metropolis is currently trading at INR 1399 on November 11, 2019 (NSE) and is trading above its 200 EMA (1107) and above its 50 EMA (1293)

Recommended Read: Finblab Value Pick Stock Polycab India Ltd

15 July, 2019

Metropolis Healthcare Limited is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan)

Metropolis Healthcare Limited: History

Established in the year 1980, Mumbai based Metropolis Healthcare Limited is a chain of diagnostics companies.

The Company mainly focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports.

It also offers customized wellness packages to our institutional customers as per their requirement.

The Company conducts its operations through its laboratory and service network.

You may like: 9 Key Financial Ratios To Find Winning Stocks

Metropolis Healthcare: Business Activities

Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles, which are used for diagnostic screening, early detection, prediction, confirmation and/or monitoring of the disease.

Its tests are broadly classified into 3 categories –

Routine tests: such as blood chemistry analyses, blood cell counts and urine examination;

Semi-specialized tests: such as thyroid function tests, viral and bacterial cultures, histology, cytology, and infectious disease tests; and

Specialized tests: such as tests for coagulation studies, autoimmunity tests, cytogenetics, and molecular diagnostics.

Metropolis also offers analytical and support services to clinical research organizations for their clinical research projects.

Read this: 5 Lessons To Learn From Long Term Investors

Metropolis Healthcare: Company Reach

FY19 continued to be a year of aggressive network expansion for the company. Its laboratory network grew to 119 from 106 in FY2018. The collection centre network grew 40% from 1756 in FY18 to 2455 in FY19.

As of March 31, 2018, the company offered a broad range of approximately 3,480 clinical laboratory tests and 524 profiles.

The Company have implemented a hub and spoke model for quick and efficient delivery of services through its widespread laboratory and service network, which covers 173 cities in India, as of March 31, 2018.

Outside India, the company has laboratory operations in Ghana, Kenya, Zambia, Mauritius, and Sri Lanka. In addition, Metropolis has also entered into agreements with 3rd parties for collection and processing of specimens in Nepal, Nigeria, UAE, and Oman.

As of March 31, 2018, the company has an operational network of 17 clinical laboratories, 28 patient touch points, and 7 ARCs, outside India.

Also Read: 7 Silly Equity Investing Mistakes of Small Investor

Listed On

The shares of Metropolis Healthcare share are presently listed at Bombay Stock Exchange (BSE); CODE 542650 and National Stock Exchange (NSE) as Metropolis

Quarterly Numbers:

The company has reported its first ever financial results after its IPO. The net profit of the company stood at INR 123.6 Cr, a jump of 10.5% over the previous year. The revenues grew 18.1% Y-o-Y to INR 760 Cr on Y-o-Y basis.

The earnings before interest, tax, depreciation and amortisation (EBITDA) stood at 26.2%.

The average realisation increased from INR 402 per test in FY18 to INR 447 per test in FY19, due to focus on more specialised tests.

Conclusion

Metropolis Healthcare Limited is one of India’s largest diagnostic chain companies.

The Management of the company is very confident in expanding the business. In an interview to Moneycontrol, Ameera Shah, Managing Director of Metropolis said the company will continue to be on fast pace expansion, and doubling market share in 5 focus cities (namely Mumbai, Pune, Chennai, Bengaluru and Surat – which constitute about 58.6% of revenues of the company) and eight seeding cities.

Promoters of the company are having a stake of more than 57 percent with 0% pledge shares. Along with that Aditya Birla Sun Life Mutual Fund is having 2.46% stake in the company.

Ace investor Radhakishan Damani through his firm Bright Star Investment Private Ltd and Smaller Cap World Fund Inc. holds 7 lakh shares and 6,86,545 shares respectively of Metropolis Healthcare.

On the technical front, the share price of Metropolis is trading well above its 50 and 200 EMA on the daily chart.

Keeping the above listed points in mind, Metropolis Healthcare Limited looks good at INR 1040. Finblab recommends investing in the stock in staggered manner for medium to long term. (One can accumulate on decline also)

If you like this article may be your friends too. Why not share it?

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Metropolis Healthcare Limited: Value Pick Stock July 2019, Update appeared first on Upcoming ipos: Latest news on stocks, economy & finance.